Repare Therapeutics (RPTX) Stock Price
Repare Therapeutics Price
Over the last 4 years Repare Therapeutics grew revenue by 346.1% annually, reaching 53.48 M USD. For Repare Therapeutics, the net margin of -158.4% is up versus -39,568.1% a few years ago. The consensus 12-month price target for Repare Therapeutics is 3.06 USD, about 15.5% above where the stock trades today. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.
Repare Therapeutics stock price
Repare Therapeutics business model & stock analysis
Frequently asked questions about Repare Therapeutics
Repare Therapeutics Inc. is a pharmaceutical company that focuses on developing precision oncology drugs. Their business model revolves around utilizing synthetic lethality, a cutting-edge approach to target specific genetic vulnerabilities in cancer cells. By exploiting the DNA repair pathways unique to cancer cells, Repare aims to develop novel therapies with enhanced efficacy and limited side effects. Their research and development efforts are driven by a robust pipeline of small molecule candidates, aiming to address the unmet medical needs of cancer patients. Repare Therapeutics Inc. is committed to revolutionizing cancer treatment through innovative precision medicine solutions.
Repare Therapeutics Inc is primarily active in the biotechnology industry.
The main competitors of Repare Therapeutics Inc in the market include leading biopharmaceutical companies like AstraZeneca, GlaxoSmithKline, Pfizer, and Novartis. These companies also focus on developing innovative and effective cancer treatments, similar to Repare Therapeutics Inc. As Repare Therapeutics Inc strives to advance its precision oncology pipeline and leverage its proprietary synthetic lethality approach, it faces competition from these established players in the industry.
Repare Therapeutics Inc is a pharmaceutical company specializing in precision oncology. Founded in 2016, the company is headquartered in Cambridge, Massachusetts, and has a research and development hub in Montreal, Canada. Repare Therapeutics aims to develop innovative drugs that target specific vulnerabilities in cancer cells through its proprietary synthetic lethality approach. With a focus on DNA repair pathways, the company harnesses the power of genomics, bioinformatics, and machine learning to identify potential drug targets. Repare Therapeutics has made significant advancements in novel therapeutics and is committed to revolutionizing cancer treatment through its cutting-edge research and development efforts.
Repare Therapeutics Inc, a leading biotechnology company, has accomplished several significant milestones. Firstly, it successfully completed its initial public offering (IPO) in June 2020, raising substantial capital to fuel its growth. Additionally, the company has made remarkable strides in advancing its innovative precision oncology platform, known as SNIPRx®, which utilizes synthetic lethality to target specific cancer vulnerabilities. Repare Therapeutics Inc has also forged strategic collaborations with renowned pharmaceutical companies, such as Bristol Myers Squibb, to further enhance its research and development efforts. These achievements demonstrate Repare Therapeutics Inc's commitment to revolutionizing cancer treatments through groundbreaking therapeutics and strategic partnerships.
Repare Therapeutics Inc primarily operates in the United States and Canada.
Repare Therapeutics Inc represents values of innovation, collaboration, and patient-centricity. As a leading biotech company, Repare is committed to revolutionizing cancer treatments through its pioneering synthetic lethality approach. By harnessing the power of precision medicine, Repare aims to develop targeted therapies that address the underlying mechanisms of DNA damage repair in cancer cells. The company's corporate philosophy emphasizes scientific excellence, integrity, and a strong sense of responsibility towards advancing human health. Repare Therapeutics Inc prioritizes the needs of patients and strives to make a significant impact in the fight against cancer through cutting-edge research and development.
Analysts currently set an average price target of 3.06 USD for the Repare Therapeutics stock (median: 3.06 USD), implying +15.5 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the Repare Therapeutics stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Repare Therapeutics to generate revenue of 6.67 M USD and earnings per share of -1.28 USD.
Converted at the current exchange rate, the Repare Therapeutics share trades at 2.36 EUR (2.65 USD).
The Repare Therapeutics share (RPTX) is listed on 1 stock exchanges, including: NASDAQ (RPTX).
The company Repare Therapeutics Inc is a rising biotechnology company specializing in the discovery and development of new drugs for the treatment of cancer. The company was founded in 2016 and is headquartered in Montreal, Canada. Repare Therapeutics' business model is based on researching the fundamental mechanisms that lead to the development of cancer. The company uses an innovative approach called Synthetic Lethality to specifically identify weaknesses in cancer cells and then develop targeted drugs against these weaknesses. The company operates in two main areas, the discovery of new drugs and the clinical development of already identified candidates. Repare Therapeutics conducts intensive research and development to discover and develop new drug candidates. These drugs are then tested in clinical studies to evaluate their effectiveness and safety. Repare Therapeutics specializes in the development of drugs against cancer types that are traditionally difficult to treat. One such cancer is prostate cancer, which often exhibits high resistance to standard chemotherapy drugs. Repare Therapeutics focuses on innovative approaches, such as the development of drugs that target specific weaknesses in the DNA of cancer cells. In addition to drug development, Repare Therapeutics also collaborates with other biotechnology and pharmaceutical companies. The goal of these partnerships is to expand Repare Therapeutics' portfolio and further advance the research and development of new drugs. Repare Therapeutics' business model is focused on research and development, aiming to develop highly effective drugs against difficult-to-treat types of cancer. The company focuses on innovative approaches to specifically identify weaknesses in cancer cells. Through partnerships with other companies, the portfolio is expanded and research and development are advanced. Overall, Repare Therapeutics is a promising company that focuses on one of the biggest challenges in medicine: the development of effective and safe drugs for the treatment of cancer. With its innovative approaches and strong partnerships, the company has the potential to play a significant role in cancer research and contribute to better treating this disease in the future.
The expected revenue of Repare Therapeutics is 6.67 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Repare Therapeutics is -54.17 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Repare Therapeutics is currently -2.07. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Repare Therapeutics stock.
The price-to-sales ratio (P/S) of Repare Therapeutics is currently 16.86. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Repare Therapeutics stock.
The Eulerpool Quality Score for Repare Therapeutics is 3/10.
The ISIN of Repare Therapeutics is US7602731025. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Repare Therapeutics is A2P7AV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Repare Therapeutics is RPTX. The ticker symbol is used to trade Repare Therapeutics shares on the stock exchange.
Repare Therapeutics stock
Repare Therapeutics Peer Group
Repare Therapeutics Ticker
Repare Therapeutics FIGI
All fundamentals and in-depth analysis of Repare Therapeutics
Our stock analysis for Repare Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Repare Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.